Revolution Medicines Inc (RVMD) concluded trading on Wednesday at a closing price of $34.60, with 3.76 million shares of worth about $130.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.70% during that period and on April 03, 2025 the price saw a gain of about 2.91%. Currently the company’s common shares owned by public are about 185.90M shares, out of which, 161.67M shares are available for trading.
Stock saw a price change of -8.27% in past 5 days and over the past one month there was a price change of -8.85%. Year-to-date (YTD), RVMD shares are showing a performance of -20.90% which increased to 9.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $29.55 but also hit the highest price of $62.40 during that period. The average intraday trading volume for Revolution Medicines Inc shares is 1.34 million. The stock is currently trading -8.79% below its 20-day simple moving average (SMA20), while that difference is down -13.44% for SMA50 and it goes to -22.27% lower than SMA200.
Revolution Medicines Inc (NASDAQ: RVMD) currently have 185.90M outstanding shares and institutions hold larger chunk of about 94.03% of that.
The stock has a current market capitalization of $6.43B and its 3Y-monthly beta is at 1.14. It has posted earnings per share of -$3.57 in the same period. It has Quick Ratio of 14.20 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVMD, volatility over the week remained 5.12% while standing at 4.37% over the month.
Stock’s fiscal year EPS is expected to drop by -27.80% while it is estimated to decrease by -6.99% in next year. EPS is likely to grow at an annualized rate of -3.26% for next 5-years, compared to annual growth of -27.80% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on July 16, 2024 offering a Buy rating for the stock and assigned a target price range of between $46 and $62 to it. Coverage by Barclays stated Revolution Medicines Inc (RVMD) stock as an Overweight in their note to investors on July 12, 2024, suggesting a price target of $52 for the stock. On July 08, 2024, Jefferies Initiated their recommendations, while on April 12, 2024, Needham Reiterated their ratings for the stock with a price target of $46. Stock get a Strong buy rating from Raymond James on April 10, 2024.
